Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B
Boston Scientific Corporation (NYSE: BSX) announced a strategic $1.5 billion investment for an approximately 34%...
Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a strategic partnership with fellow Chinese biopharmaceutical company...
Lundbeck’s Asedebart Receives Japanese Orphan Drug Designation for Congenital Adrenal Hyperplasia and Cushing’s Disease
Lundbeck (OTCMKTS: HLUBF) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted...
Leads Biolabs’ Opamtistomig Becomes World’s First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC
Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced it has received regulatory clearance in China...
CSPC Pharmaceutical Receives NMPA Clinical Trial Approval for SYH2095, World’s First KAT6 Inhibitor
CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received clinical trial approval from China’s...
Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting “Undruggable” Proteins
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a strategic research collaboration with Parabilis Medicines to discover...
Boehringer Ingelheim’s JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis
Boehringer Ingelheim (BI) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted...
Bayer’s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment
Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted...
Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline
Zhejiang Shimai Pharmaceutical Co., Ltd., a T-cell engager (TCE) specialist founded in 2017, has filed...
Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval
Suzhou Sanegene Bio Inc., an RNAi specialist with R&D centers in the U.S. and China,...
Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town
Youcare Pharmaceutical Group (SHA: 688658) announced a RMB 1 billion ($147 million) investment to establish...
Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the Phase III SHR-A2009-301...
BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader
BrightGene (Suzhou) Bio-Medical Technology Co., Ltd. (SHA: 688166) has filed its prospectus with the Hong...
China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases
China’s National Healthcare Security Administration (NHSA) and Ministry of Finance jointly issued a comprehensive notice...
Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial
Merck & Co., Inc. (MSD) (NYSE: MRK) announced that the pivotal Phase 3 TroFuse-005 trial...
Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem
Bayzed Health Group (HKG: 2609) and Meinian Onehealth Healthcare (Group) Co., Ltd. (SHE: 002044) announced...
Ande Healthcare Files Hong Kong IPO Prospectus as Leading Chinese Medical Consumables Innovator
Shandong Ande Healthcare Apparatus Co., Ltd. has released its prospectus and formally applied for listing...
GSK’s Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW)...
Taiji Industry Secures NMPA Clinical Trial Approval for DSC158A, Next-Generation Influenza RNA Polymerase Inhibitor
Chongqing Taiji Industry (Group) Co., Ltd. (SHA: 600129) announced that China’s National Medical Products Administration...
Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial
Accro Bioscience (Suzhou) Limited announced the completion of a $50 million Series C financing round,...